Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice

Journal of Clinical Investigation

Volumn 121, Issue 9, 2011, Pages 3756-3762

  O'Brien, W Timothy ^a   Huang, Jian ^a   Buccafusca, Roberto ^b   Garskof, Julie ^a   Valvezan, Alexander J ^a   Berry, Gerard T ^b   Klein, Peter S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN KINASE B;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SENSITIVITY ANALYSIS;

ANIMALS; ARRESTINS; BEHAVIOR, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 80052346263     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45194     Document Type: Article

References (61)

1. Gould T.D., Manji H.K. The Wnt signaling pathway in bipolar disorder. Neuroscientist. 2002;8(5):497-511.
2. Cade J. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349-352.
3. Schou M. Lithium treatment at 52. J Affect Disord. 2001;67(1-3):21-32. (Pubitemid 34183334)
4. Pilcher H.R. Drug research: The ups and downs of lithium. Nature. 2003;425(6954):118-120. (Pubitemid 37150871)
5. O'Brien W.T., Klein P.S. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans. 2009;37(Pt 5):1133-1138.
6. Berridge M.J., Downes C.P., Hanley M.R. Neural and developmental actions of lithium: A unifying hypothesis. Cell. 1989;59(3):411-419. (Pubitemid 19284456)
7. York J.D., Guo S., Odom A.R., Spiegelberg B.D., Stolz L.E. An expanded view of inositol signaling. Adv Enzyme Regul. 2001;41:57-71.
8. Gurvich N., Klein P.S. Lithium and valproic acid: Parallels and contrasts in diverse signaling contexts. Pharmacol Ther. 2002;96(1):45-66. (Pubitemid 35346617)
9. Williams R.S., Cheng L., Mudge A.W., Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature. 2002;417(6886):292-295. (Pubitemid 34534711)
10. Tanizawa Y., Kuhara A., Inada H., Kodama E., Mizuno T., Mori I. Inositol monophosphatase regulates localization of synaptic components and behavior in the mature nervous system of C. elegans. Genes Dev. 2006;20(23):3296-3310. (Pubitemid 44904851)
11. Acharya S., Bussel J.B. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000;22(1):62-65. (Pubitemid 32266840)
12. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93(16):8455-8459. (Pubitemid 26269579)
13. Beaulieu J.M., et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008;132(1):125-136.
14. Hedgepeth C., Conrad L., Zhang Z., Huang H., Lee V., Klein P. Activation of the Wnt signaling pathway: A molecular mechanism for lithium action. Dev Biol. 1997;185(1):82-91. (Pubitemid 27244219)
15. Stambolic V., Ruel L., Woodgett J. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6(12):1664-1668. (Pubitemid 27050234)
16. Munoz-Montano J.R., Moreno F.J., Avila J., Diaz- Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 1997;411(2-3):183-188. (Pubitemid 27301451)
17. Hong M., Chen D.C., Klein P.S., Lee VM-Y. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem. 1997;272(40):25326-25332. (Pubitemid 27415724)
18. Lovestone S., Hartley C.L., Pearce J., Anderton B.H. Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: The effects on the organization and stability of microtubules. NeuroScience. 1996;73(4):1145-1157. (Pubitemid 26194338)
19. Mudher A., et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry. 2004;9(5):522-530. (Pubitemid 38903508)
20. O'Brien W.T., et al. Glycogen synthase kinase- 3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J NeuroSci. 2004; 24(30):6791-6798. (Pubitemid 38993901)
21. Meijer L., et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol. 2003; 10(12):1255-1266. (Pubitemid 38050973)
22. Hedgepeth C.M., Deardorff M.A., Rankin K., Klein P.S. Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin. Mol Cell Biol. 1999;19(10):7147-7157. (Pubitemid 29441895)
23. Williams D.S., Atilla G.E., Bregman H., Arzoumanian A., Klein P.S., Meggers E. Switching on a signaling pathway with an organoruthenium complex. Angew Chem Int Ed Engl. 2005;44(13):1984-1987. (Pubitemid 40483015)
24. Harwood A.J., Plyte S.E., Woodgett J., Strutt H., Kay R.R. Glycogen synthase kinase 3 regulates cell fate in Dictyostelium. Cell. 1995;80(1):139-148.
25. Cohen E.D., et al. Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. J Clin Invest. 2007;117(7):1794-1804. (Pubitemid 47036313)
26. Doble B.W., Patel S., Wood G.A., Kockeritz L.K., Woodgett J.R. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell. 2007;12(6):957-971. (Pubitemid 46805920)
27. Pierce S.B., Kimelman D. Regulation of Spemann organizer formation by the intracellular kinase Xgsk-3. Development. 1995;121(3):755-765.
28. He X., Saint-Jeannet J-P, Woodgett J.R., Varmus H.E., Dawid I.B. Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos. Nature. 1995;374(6523):617-622.
29. Dominguez I., Itoh K., Sokol S.Y. Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos. Proc Natl Acad Sci U S A. 1995;92(18):8498-8502.
30. Noble W., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A. 2005;102(19):6990-6995. (Pubitemid 40675429)
31. De Sarno P., Li X., Jope R.S. Regulation of Akt and glycogen synthase kinase-3beta phosphorylation by sodium valproate and lithium. Neuropharmacology. 2002;43(7):1158-1164. (Pubitemid 36009369)
32. Li X., et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: Implication in the treatment of bipolar disorder. Biol Psychiatry. 2007;61(2):216-222. (Pubitemid 46072775)
33. Polter A., et al. Deficiency in the inhibitory serinephosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology. 2010;35(8):1761-1774.
34. Beaulieu J.M., et al. Lithium antagonizes dopaminedependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A. 2004;101(14):5099-5104.
35. Gould T.D., Einat H., Bhat R., Manji H.K. ARA014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol. 2004;7(4):387-390. (Pubitemid 39648068)
36. Kaidanovich-Beilin O., Milman A., Weizman A., Pick C.G., Eldar-Finkelman H. Rapid antidepressivelike activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry. 2004;55(8):781-784. (Pubitemid 38429867)
37. Weiner I., Schiller D., Gaisler-Salomon I., Green A., Joel D. A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine. Behav Pharmacol. 2003;14(3):215-222. (Pubitemid 36735154)
38. Beaulieu J.M., Caron M.G. Looking at lithium: molecular moods and complex behaviour. Mol Interv. 2008;8(5):230-241.
39. Borchelt D.R., et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet Anal. 1996;13(6):159-163. (Pubitemid 27063321)
40. Ma T., et al. Statin's excitoprotection is mediated by sAPP and the subsequent attenuation of calpaininduced truncation events, likely via rho-ROCK signaling. J Neurosci. 2009;29(36):11226-11236.
41. Goñi-Oliver P., Lucas J.J., Avila J., Hernández F. N-terminal cleavage of GSK-3 by calpain: A new form of GSK-3 regulation. J Biol Chem. 2007;282(31):22406-22413. (Pubitemid 47267365)
42. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229(2):327-336. (Pubitemid 8225714)
43. Beaulieu J.M., et al. Reply to Belmaker et al.: GSK3 haploinsufficiency results in lithium-like effects in the forced-swim test. Proc Natl Acad Sci U S A. 2008;105(20):E24.
44. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., Caron M.G. An Akt/betaarrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122(2):261-273. (Pubitemid 41032989)
45. Beaulieu J.M., et al. Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J NeuroSci. 2007;27(4):881-885.
46. Kovacs J.J., Hara M.R., Davenport C.L., Kim J., Lefkowitz R.J. Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell. 2009;17(4):443-458.
47. DeFea K.A. Beta-arrestins as regulators of signal termination and transduction: how do they determine what to scaffold? Cell Signal. 2011;23(4):621-629.
48. Doble B.W., Woodgett J.R. GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003; 116(pt 7):1175-1186. (Pubitemid 36410657)
49. Sim A.T., Scott J.D. Targeting of PKA, PKC and protein phosphatases to cellular microdomains. Cell Calcium. 1999;26(5):209-217. (Pubitemid 30003785)
50. Kikuchi A. Roles of axin in the Wnt signalling pathway. Cell Signal. 1999;11(11):777-788. (Pubitemid 29507486)
51. Li X., et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: Implication in the treatment of bipolar disorder. Biol Psychiatry. 2007;61(2):216-222. (Pubitemid 46072775)
52. Mohammad M.K., et al. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation. Eur J Pharmacol. 2008;584(1):185-191.
53. Prickaerts J., et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: A putative model of hyperactivity and mania. J NeuroSci. 2006;26(35):9022-9029. (Pubitemid 44319393)
54. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation, and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001;20(1-2):27-39. (Pubitemid 32099099)
55. Ackermann T.F., Kempe D.S., Lang F., Lang U.E. Hyperactivity and enhanced curiosity of mice expressing PKB/SGK-resistant glycogen synthase kinase-3 (GSK-3). Cell Physiol Biochem. 2010;25(6):775-786.
56. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate- induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A. 1999;96(15):8745-8750. (Pubitemid 29354862)
57. Zhang F., Phiel C.J., Spece L., Gurvich N., Klein P.S. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem. 2003;278(35):33067-33077. (Pubitemid 37055753)
58. Bersudsky Y., Shaldubina A., Kozlovsky N., Woodgett J.R., Agam G., Belmaker R.H. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: Negative results. Behav Pharmacol. 2008; 19(3):217-224. (Pubitemid 351670402)
59. Gould T.D., O'Donnell K.C., Picchini A.M., Manji H.K. Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: A mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology. 2007;32(6):1321-1333. (Pubitemid 46788857)
60. Sasaki Y., Vohra B.P., Baloh R.H., Milbrandt J. Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo. J NeuroSci. 2009;29(20):6526-6534.
61. Tao Y.S., Edwards R.A., Tubb B., Wang S., Bryan J., McCrea P.D. beta-Catenin associates with the actinbundling protein fascin in a noncadherin complex. J Cell Biol. 1996;134(5):1271-1281. (Pubitemid 26300171)